Abstract 658P
Background
Oncolytic viruses have the potential to synergize with immune checkpoint inhibitors (ICI), especially when engineered to express immunomodulatory payloads. ONCR-177 is a next-generation oncolytic Herpes Simplex Virus-1 (oHSV-1) intended for intratumoral (IT) administration, developed to target solid tumors, in monotherapy and in combination with ICI.
Methods
A first-in-human phase 1 trial (NCT04348916) of IT ONCR-177 alone and in combination with pembrolizumab in patients (pts) with advanced cutaneous, subcutaneous or metastatic solid tumors (surface lesions), and liver metastases (visceral lesions) was performed. Primary objectives were safety, tolerability, and determination of the recommended Phase 2 dose (RP2D) of ONCR-177 alone and in combination with pembrolizumab. Secondary objectives were anti-tumor activity (RECIST v1.1), viral shedding and cytokine levels detection.
Results
A total of 66 pts, with a median age of 63, 55% females and with 13 different tumor types (most frequent breast cancer 30%) were enrolled (N=56 in surface and N=10 in visceral lesions cohort). Sixty-two pts were evaluable for safety. No dose-limiting toxicities (DLTs) were reported through different dose levels (DL) up to 4x108 PFU in 4ml, which was defined as RP2D. The most common treatment-related adverse events (TRAEs) were cytokine release syndrome (CRS), in 14 pts (23%) or symptoms of fever, hypotension, and chills in 32 pts (52%). Only 1 pt had grade (G)3 CRS. Other TRAEs included G1/2 fatigue (37%). A total of 61 pts were evaluable for response, with 5 responders, all at RP2D and in surface lesions, 3 (5%) complete responses (CR) and 2 (3%) partial responses (PR), all previously exposed to ICI. Two CR were achieved in combination cohort. At RP2D, a trend towards higher plasma IFNγ levels and CRS-related AEs was observed, although no payload above physiologically relevant levels was detected.
Conclusions
ONCR-177 was safe to administer to surface and visceral lesions either as monotherapy or in combination with Pembrolizumab. Local responses were observed, although sustainable efficacy could not be achieved in a systemic manner in these heavily pretreated pts.
Clinical trial identification
NCT04348916.
Editorial acknowledgement
Legal entity responsible for the study
Oncorus.
Funding
Oncorus.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01